在患有扩散型大B细胞淋巴瘤的患者中,使用R-CHOP治疗完全缓解的频率
Sani U Hassan1, Shah Hussain1, Mahnoor Fakhar2
1Department of Medical Oncology, Hayatabad Medical Complex Peshawar, Peshawar, PAK.
Cureus
|May 2, 2024
概括
第一线R-CHOP治疗在84.2%的扩散型大B细胞淋巴瘤患者中实现了完全缓解. 需要进一步的研究来解决晚期不良影响,并改善这种异质癌症的结果.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 呈现出显著的异质性,使预后和治疗策略复杂化.
- 目前的分子亚型和预后评估在最佳DLBCL管理方面存在不确定性.
- 局部研究对于了解特定患者队伍的治疗反应至关重要.
研究的目的:
- 在接受一线R-CHOP治疗的成年DLBCL患者中确定完全缓解率 (CR).
- 评估Rituximab,环胺,多克索鲁比辛,温克里斯和普雷迪尼索隆 (R-CHOP) 在一个定义的患者群体中的疗效.
主要方法:
- 在巴基斯坦佩沙瓦的哈耶塔巴德医疗综合体进行了一项描述性研究.
- 新诊断的DLBCL患者年龄在20-70岁之间,未接受过治疗,从2022年8月到2023年4月被录取.
- 收集的数据包括人口统计,疾病持续时间和CR结果.
主要成果:
- 在R-CHOP治疗后观察到高CR率84.2% (80名患者).
- 大多数患者 (63.2%) 的疾病持续时间≤3个月.
- 患者人口统计包括年龄分布和BMI分类,51.6%的BMI为18.5-24.9 kg/m2.
结论:
- R-CHOP疗法在实现DLBCL患者的CR方面表现出显著的有效性.
- DLBCL是一种异质的疾病,尽管有希望的R-CHOP疗效,但结果是可变的.
- 需要进一步的研究来探索预后标志物和替代治疗方法,以减轻晚期不良影响并改善全球DLBCL的结果.
更多相关视频
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
29.3K
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...